[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "In cases of sudden remission of idiopathic intracranial hypertension, if the patient continues to take acetazolamide to lower their intracranial pressure, what will be observed on an intraocular pressure test?\n\nAnswer Choices:\nA. High intraocular pressure\nB. Low intraocular pressure\nC. Normal intraocular pressure\nD. Low intracranial pressure\nE. High intracranial pressure"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762210758-6Aaz60Ll1EZJC1QVGqAU",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"B. Low intraocular pressure. Acetazolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production, so continued use will lower intraocular pressure on testing.\",\"answer_letter\":\"B\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Considering IOP effects**\n\nIf the patient continues taking acetazolamide, the intraocular pressure (IOP) will be low. So, I think the answer is B: Low intraocular pressure. The reasoning here is that even in IIH remission, continuing acetazolamide reduces aqueous humor production, which leads to a lower IOP as observed in testing. Acetazolamide works by decreasing aqueous production, thus lowering the IOP. I\u2019ll make sure the formatting is minimal while including answer letter B and a brief rationale.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Considering IOP effects**\n\nIf the patient continues taking acetazolamide, the intraocular pressure (IOP) will be low. So, I think the answer is B: Low intraocular pressure. The reasoning here is that even in IIH remission, continuing acetazolamide reduces aqueous humor production, which leads to a lower IOP as observed in testing. Acetazolamide works by decreasing aqueous production, thus lowering the IOP. I\u2019ll make sure the formatting is minimal while including answer letter B and a brief rationale.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCTPPlLjtgEx7A43SHYtlAAU2vN_WaJVqwWtZqgNwEm_8SHUCoJYzXK6T51Por3YjgaILK_v2lvpHuk3Gy-Sywpl63Z-bNovZ7jQBKV6XR7sZAqS_hMooAMnIf8UwLfJ4BBMYMi6M2N-_-_uJRCx-PL1fLPCWvDMvIviMUDeW-76nDXbjdb3oas8z0QI7QnA5ZAu0Dc_8ga3YLYNzll3F1VkVlglFwRLyj03kTEF3zwfd8_fBYKQlD0ZRyPA44CD8L5bXLpBU_cITBiFSvcYSJhpBJBD_g8WDp4ck7XDynf-224Kz17bLLyONRiWgzCXFAFKjTB4WK4uexfalnodCsf5IdQ_siQMpCxlrcbH4KcnoqsKJZyZUr137dsfOJO8tnQfNPK_SQqROnhVosqrAXjffrBPf-_K44ttJN11Z7bGapJwf8EyS84AFDnIq-XU6b7WrBpJXz95fYFd6_tnKVZKHNWzB7FEYrqBAIBDJtqV7loF4LrsT0EZaq2bi4W-NPeGSqCo14nfvRTxlO_Fimd74OLC6cQkgFScS2o7eM4rC-Szn29vadYATPGL4wLgZmJjxcqPGyjlxmGCTSG8rpq1H6HjHA336XTnezzvdrNwYRV8JL2eIVSg-xZmf0E4UEbS4U_J9C0zHi6OsKqI-qSafTK1aL1FPr9FzQveFZEXyRUadBNVthGc0yrf3s8iQfId9CLSHbsOJ84CN5YOZbj_uBLhzlKGo_Azc1sObjH4rX7xLvBawsMEiLMbVHI3C5V3rW0E3caTc4-d_bRr8wNdUrIR1ZQdjIoKBRQSStQwEQWiaxlyU6uDbSDtogIZ3CGH129yhFUWfie4N8LsmUrOEcF_qR3ceziwIu24_RgyLW8RR5KIQ8mv80uXWybSSuXoAvgyR_CSGGrM7u9QA0_zJRQ8a6iH66y3IobYVUxBw4FLIZsIyqGQ2VQlH1Z5RrswECSphQqp1FwH-EQArDbx7la81QbEl9iL9Cw3H_7ybDcLFD1fdi_J8XlluSY5qovHK3BJaMx0hveS3z5R3VsFbuVzWG3zQ12mp-f-_rg8zfSZSuYlcT5UmJeC46O6MZNiM536sGjonPtAcRXFKQcaOHR0S3yWdjJ0FsyXBrXKi9klOcKOl7shlHXFL7F4S6rIbSi2UMDlTbfUE64IxNQJjAD3kcUGepiBf4KokSKLiM0HbAjP3veLUfgx3dSUgjjlv7_bARvBC3_fqD775zgtCDCrGmoSlo1eT1cd7Ek_4sRvt7akS47-qeqsj4ehOJIzDKpWGYDBRxcTjyQc6VuIAgbG81OFJbXf6Jd02XLQhKdmAEeT8mufKaiE-I2RJ9Is66b3-WXkfyrhwoRcmShxjgM1JsDkIf_JgCJOXqVF8budVHYgEV5BOtyqcsjtu4WAS2YEig2YcYOmoWU3s_cMoDJGY7r0CK3GiyZu3UtpVkrxQe5vwsediPdQ2zEqVUnVioqav6_fDU6hlTBpr4zREpAe4e6w7sYh9nw5VvJfyrGLJsRT5oqnc_0UJtCGzNKF26Ost-3vjWYa9u2lORBSg8tHFkvzsXB-G3KGjP9HrOxtED5ke0NgqnhdaI9MIw3ONV29HbXCzWR10xm3oCS7rnPsnZ3tqwX2jKjmczK6Ue5O-DGpt0dhgJJe7ok0c4_3ndWe52k8ZfmDxQCTRFEVaMApKUd-HWwxD0Zgt1YjMNDXdQY5WjTZpm4z7ljDKQ8thXi-xm4hJxyuxgtQRyHc1j_TSqw9ht9CBAj2yt5G77q1Cgl_3cuF26Q_CBveTdadgO9SYDuUQeyaRu11xCF_lX1tEosnkXXRyfRJYwo38-1udFaiLJmhTiVrXEdGjCpYsOsNk891Q5IZKnfmbEeHOLJb_5g4ZWjaX7ot6aZAryvGP5Dugqrf9X1HiAMK9Oezn2ksiH0GfYjVcFHoWbCKkKS1OP6C4Ro97i3-FMp-nhfzBUMDTaNaplBRzmzkgkK9aMyIQ15d_r366lujPYTdyUyABLUzkqryLPNTtwv5EqxyXejcUAzv8KzzThIUJypTBKuyLrbXxx0Y0o0yb-GCNZ9jHdFaAmXg1WVzNk8-H2Nkzsb4pzackNmeqiRg74zmpatvXKymH6E_H2YMJfVrothdH8_EcnIcBDH958yvnVtMe4EywZFftn1rADgrOMp3BPY-4vjzc1AYltwUyiijZkgUTROcIVbEoa1RXdzi45_xAIIJAZlcg4AGT72ZAqjpQr0fFhAWWVAG1rZ8vwV54_hc2CoFjqyhGvN5PGOr3H5ehRT6-id615e13-0-k1F9x-azZSCeyqKVOkOTaLGl_b61CaVgsS55KHu_HchVp_-IH-nLHvr7dPTUiO1k0D8dnHr79IW-cir9RoprPbTWZxE5IW6RUjgyWAvI7ZHodxEAPJPv8aSfjUAxiaKWSgOviz9k-rgl2zgJm8Pg9piFYVv4iwhiJiq7s0j4FLsQHY-3ewUCDpaMB9uPtbvuahW3SY6THTZPC6uFH9o2VJ7xeCPpq_ee7bu613i3Cd-yucpDP7U66Es7rEFWhVOtOF0StdgBmvH6LNsyr8-uLYOUnIbwzVEYZU38XpLvd20aXFgJjpGjnJEaAAML-KZ68B-YRDkTXiJLaeBi283-GsWdYs0cx85UAzgXAisA-VrW-_7UcuIuMlbgzZs6C0DcqbT_v5ksMdHVgAgcyNYyrjAnCP5dPsZejGL_LrOvjCXK-65blPXdCCyb8T45E2FAjTRgp3jMGkZ6TCJr1R8d2OY2LwtQocYiPpmQdwK6nyj4O2bxAq3AbmABOSQQG1CAFLqK4DOTvWzQNdfQtw68x6LhJKxoLVl_6ovlAeqPSwfBcKUWk1908_hQsw1Sak-pQyDmaYV5nBFvcYWhRzaln_Pn7w7hbvD8kqmTNXyHu0GUkaKgzLAGdP50500utyndc1yD2Z4fOYMIEevIXujzFyL5MJA==",
                "id": "rs_05fe04312078936901690933c6e7cc81958003e14329110aff",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762210758,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 373,
        "prompt_tokens": 128,
        "total_tokens": 501,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 320,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.000778,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 3.2e-05,
          "upstream_inference_completions_cost": 0.000746
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "In cases of sudden remission of idiopathic intracranial hypertension, if the patient continues to take acetazolamide to lower their intracranial pressure, what will be observed on an intraocular pressure test?\n\nAnswer Choices:\nA. High intraocular pressure\nB. Low intraocular pressure\nC. Normal intraocular pressure\nD. Low intracranial pressure\nE. High intracranial pressure"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762210758-CE4FYOdOjsUMz0tuztX1",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"Low intraocular pressure. Acetazolamide (a carbonic anhydrase inhibitor) reduces aqueous humor production and thus lowers intraocular pressure, so IOP would be reduced.\",\"answer_letter\":\"B\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": null,
            "reasoning_details": [
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCTPLrfR68l-SKm-T012HeImlaJHIWxuPtlhGfZy9dUuGWpG9nPNiiNHZW_TkZGK1fY2a28SzI0dn9PAvbVq0AnH8wpC6jbEthMj4pPPza4PK4vDIGOBnWK5gLR7Rlhq0SL44c8X_Aosr95YICIu8OfbeOwfit3pYcuCpGqv9hPXHbRN0-aTuwufxXxIqqr6-Y160o8dNlLx3oyfDaivX7DjibkMdzikOY5xIyuuWH_CJ7mQxxMExoJPWHhuD24dVbT4NDKs7DW-bI4p0SDvKM5eDlZ3_b7IctdRAlueUdryl6fwkDOIOo3KC-rS3AFoKZx0fVS4UhdWNH7Fswz3PBppbem4QjRwymNsP1O7JzLk_dpXyZCGlSKhEuY9VDvGFadwZ3BzwfnL1XhPsLfr4y-ouJVG-x2sY39tFVFtGZ0iXv_W33B32tBgdx5blMa_FJydrgbksdHq94fxq4g2IwUGTaiatJKj1lSRaenmyCzMD2_cm96fjY53X7fItdYUXdw73X7uF_EibSkHsFsLOyJhuAmJaLrlclqV-2NC4R23ZVXBEV4UUGyi3X8GL6vq1Y1BMeBuvVgZ94XMxLHBf7neKN5sESFOQAmRF-KZT2Y32LcDNgR4DWtS_UfiToGn-hTTbWC6QHf7ZcPrnK3Wx1o3YVGrTvrF-_iumBxmbWB0_321loHZgBOn5v2ZUjp4d3YPkjyPC-tQeUZALhZfd05mAtY1R8XCGKItOFbC2i5AaDrHSRzDWzKi_hpQvE_0xU7H6HJOjOzgYZU9EGyh_QBMKnKuq3fw5cYh5RanNQCg_-p-5x-Q83gungtQV9tsRsTw4mvYCkB6Z5tfjtAabGFQjayDgK9bL5iVuedA-LlUPD8UJLbtlueicn9AYvcmw_KOYMsqj5UlFCVT4CmGeDZgoLPXJd5h24dLnFbWKfc-x_NNzknDxychkgWDnZE6yG3f-aOTdrjSzXeihD0lbogozx10qusA50bYGjxZ8cuOjhBLjS-9np6wF-hYwtmxAtJ6GKWNzjbK17auoW-FDbgbALRxpp6YsVVp6Er2NcKh4AQOMOe5Z1AMOkqYLNFLaljZRWBDp33We2SoPIOq4uufz18-Chtpqn-5IXndlTWDfOmp2FKpt5I_AmgfOUireAQnJqqE7SjeriG_wJYkxD4U3UjfMthic2dqwNsBo2rhTiPzSPOwSLAH8Pvf1k1E9PuKC4H7qZBGTIHgEfwWaY_oF3Qga8tocV3ZIjrmXz-Xc9RfAOZt45yzudj7FxH3G3G3HcH_yV2r6lmeZyGEdd7eT4j9Qg84FustittBH_6sqhHgl1-gCwEzIlWTmit7W0zB57CSC1XZsYH6Q4Ozx4zrAembBzur2oVB0D012ku5tjusHdX9FzvPRCgNR-hj1uYZ5nnHNob0dheW25tn19_4KWI47YHz9HKbobsoIjC7oD5xb4NhF5U65NwMkR8b8NhWURm1h7JZRN9J8doeAVwcRR6hDOWocoRXr-apx9vH7XL5emle0VU0LXaPhmX8eOxbETyMvmsJRcayH2Ql1-j08ZW8gU-RQ8JHhayOsHNpdcewIMWOZMRug-vm0JB6q1-1f4aSbu70hc_J2Js-mamK_gwQoaHz__LCAhdeXoG_Bb274f6yOF0eFCMoITWdwSBNXCiaTYgxusYHWONLgIIvOBkf4nq-la2gPNG59fKyXVTHtTKA83ZyJLK4ii30Bl756w_QoRtzo00fXe3MRuR5rbP50dalrwrOjOSSe20cYO1XlgD81JR6HidzI7hBu2elY_62uPEFiT36yqQeNNHvY6Pm_vFOvI6rah72yNKexVnxul362ywtnJf0UhFgCTf-DhD56Ym1P-QUNQHoscXDvdvqhAd_ABYNmHIs_zObuQwOChtDQBdEIiNr8ZAKDcSH5dWQOG6mn6yMgXyHBm4Xdic8kVLeIgNWGXNhqA_3IALGvso24OKMwpb1IPTkLiar4br6gUzmLK9dBKwm-yqKoAJntiXdiAM1rsugDVRTfGGphDJ7RLzxmwmcvIg-5-CMftc7e_rBdzHoo-PhFgu6M7srtGZ0x3vXOSVSQOOmgpSrP_uXS7zVWAkq0kpxPHKbPFwQ1nbsZVxTGPG3M2r4n9_4oe40c0iIZAF3TkLKsfCDMEixYzUFr2PgbYVo5OrfaoJLcsxq2Mi0rz5hVIZQ_vKIb3kcD1pQXHjdSI4pUw9wpyb7FKF0JOat6TXex5OzM",
                "id": "rs_010e7e22000966b101690933c790508196a94a91d71401570f",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762210758,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 245,
        "prompt_tokens": 128,
        "total_tokens": 373,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 192,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.000522,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 3.2e-05,
          "upstream_inference_completions_cost": 0.00049
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "In cases of sudden remission of idiopathic intracranial hypertension, if the patient continues to take acetazolamide to lower their intracranial pressure, what will be observed on an intraocular pressure test?\n\nAnswer Choices:\nA. High intraocular pressure\nB. Low intraocular pressure\nC. Normal intraocular pressure\nD. Low intracranial pressure\nE. High intracranial pressure"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762210758-FgfFA0ltP7ouZfq1qOka",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"B. Low intraocular pressure. Acetazolamide (a carbonic anhydrase inhibitor) reduces aqueous humor production as well as CSF production, so continued use will lower intraocular pressure (as measured by tonometry).\",\"answer_letter\":\"B\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating acetazolamide effects**\n\nAcetazolamide lowers intraocular pressure (IOP), but the question specifically asks about IOP testing, which doesn't measure intracranial pressure. So, option B makes sense here. It reduces the secretion of aqueous humor by the ciliary body, which is useful in glaucoma treatment, resulting in low IOP on tonometry. Thus, I\u2019ll create a final JSON with the answer string and letter, including a brief explanation that acetazolamide reduces both cerebrospinal fluid and aqueous humor, leading to lower IOP. So, it\u2019s option B.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating acetazolamide effects**\n\nAcetazolamide lowers intraocular pressure (IOP), but the question specifically asks about IOP testing, which doesn't measure intracranial pressure. So, option B makes sense here. It reduces the secretion of aqueous humor by the ciliary body, which is useful in glaucoma treatment, resulting in low IOP on tonometry. Thus, I\u2019ll create a final JSON with the answer string and letter, including a brief explanation that acetazolamide reduces both cerebrospinal fluid and aqueous humor, leading to lower IOP. So, it\u2019s option B.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCTPSRk11hrarAJnGA2xyRzGN0O4Zx1mfz56zgBuendFnYgZ9CBv9FVLlZ9r748BnV_aeOhv309jJgkDV9OAEI80fO7hnj1TtIWsdgSEP2V_pkUF3sI41YXgjmP163g-Jjw2cWH_onUlYV1iUmMTGTs89YezE3tYqHhHJ3SsaVqlpZCoGf0IxxZfHhLnwpi2rWZzCOAYmhwFwVnLPA0n1_-QLa-q6IDc7wMCgHq4rIJlv1qYI0tEldz6wZzh6yuZcIgQaApbx1eaHw-eKpRgOnf0RDsIjh--FyqJIffT4u9ubdfKSFwSCNp5gcATbkC1vqTegADTGb2hblzFi2YijFE4grE2I2XLEOLaytcz1NFjwWuvj3czQ91AyE2_vS93kPYWFSYyqSBqcK9IA3XR9NAEOHjwAgDsly_Ka2jkpoOu7HoZx0i2nw7HuKEZ62Phf6TFFfpqUopRxk6iejIcatTCaKQZ1UI4GCL163vDHbbaNL1_MNZ_uLS_SuVb1-LG1u_dF7h7ci7FEccCOZmp4ghfzsAFt2G5oGunDvnrPZz4JNNFzO5TAYlG-OTt5HwEAWDJpzCH_yyoz3XxHHHKMfCG_LVhT7cT89RxeFaj3Af2sv4lnD1gbncI-GN0rx5J5gXv-YxG8jQe6nWT4ZJaUhf-J2eerljviDD9XV5CscdkkV6UE15S6W-iD3jKN1MddcrIo9GVapNduDGQ4uoQxDN20HVKN7P0Vz4bA7N3yHZTkEbo4sKzL_uzko90IAQavoe9Nw8cW1ePjzcXiSMNwlQhkNyHLAvgmIfdKKpdEd4nPlTI4ufogU_Kw3GuDSFSnvuVvEf7MNxOifdcEopbVBGNRShcWb-VC-OmVmca-o-XM_OX2Q-vH0mgnzDVs9_Z5kN-dTcmqMJFiz8B50CEuNL-LnZof7TOuFqoOk4TFWQxPZb9gwjXf3ZPpgH4_kknsyJogyaNyFGRdbK6r9ZhpIjAy8AvoDPV-wLXzvUapCty8K-JFDuptEaiDvZcxqWASQvG05HMC6hJWEa6acONoPBF8UiDlzeBTKEvkCC1TTBrECHGECL777_-Exsek1uf8F0BuC71L4_mGOMp2X_cNcsQibNHpbKafh9s-BPmp1oG1YVwGZy-gLiYweVi5rDBfcVYnhrmVFOiWq0B4HWNbz8YQlXSite80gXJ1PUikt7_jAyMdBfNQ0jOfJUEXQSViP2OyM3BRy25-jgvBwK60cHJ3OzbM0CODLwUay7W8vUK8FF1qCyk_TK_04x8qTtYV_Pd92ricc-4a_QKQZAqgIsf8H7K0lrvtoCxMl2e2TazBcKwItO-UCLg-3bpCuiwUe6g7qOA1Pfh4URXHt8JJCfE9_VBQZIw1S6wKMNAMEqcakrsXtFtV49sTeZpMuR0SN6hhsmQ1jMkkd_SST8lj59EShjfUOUQ6Cog2hgrumrXuodZdJUkK8nUxFgvcRL3GkVJiAgy6ChZeqPUz6yiutwU6BWULwl8KpDJbip3BMcmBd32uL3M0Qq4VVL3pmCF-qECUwxYBz5kBagg0QErZpiHSnHFsaUPjMkN6tzA1DNd7c1VQ0uF5Zr1_sSgQckWKrAoxLnuRYeU2w8WrvuJeqPYYkOEAznAWY6BDp5OENFIWPCfp-VahtfBE1-6mwRzBKDQn4TFCg-iEjjMnPN17yB0CrLfnmE3aMQxwxdRpEc5j4JfaV4vBjBTM_mB4BukY1WL9xGHAxLT7r0w50ZYXNVMGW1L1CcZw6Polc2GQdMSA4va6deFe9IH_wu9aikTQDEs4hTA8MOTNCQ6O4mf7YbvbQhuuq_n-_Y191RZeTIBpmmufOQBkVawHq-3aAMvlopcv7BDwTqazN9Z5yCyLaMByiJiMZhErs4sv6aEwlkC6QvIBnEaVwpVgGhAL5dv1PZ3LwMhzCygCPLnbMMRX55YVvwdUS-1395gmx3ePWQtk4ZpUWwWmGK6gwwkv5BALOKihvJIsnM0snTDHgx5tgSadr3rEiUsU4pZ63sFhS-19Scuu7jD6n8G38ONF6w-0NvVsxMS_toMB83Olkj-hFul6MqeJ6J5h54gN9CpJIXVN5Yg6MTQGul3V1bwMaCJToDiat1s5-WopKk7fp3ufZNxBiMkzIYnBOG0BDuXv1eN75_Br_eWbVGUtuUGim7LpGiAwQqr8OzZi2PvaDw5Lj8axT6XR4O2hJ6-8EYUaSwIk8OR7L8lMtY0Ks9cpxTElXg7wqhvz3-swSejwwLd5kwI4yaEyGYqvg8N_F-Ml7ANkDwjc7zNUeBvZZk5-dJdzcO-higvBaA-585UpL0AkJU66hn9-cQYy3iZG3RUfAo2GcXFl0wCw4TAOAtu_tQwHcq5Zt7lpt2muacE1c2RqXmO0Zo7ggjdU3ivfnvXNTVv-Qaoxbqwdd9wFivB3Y221SE7PPZXpUksI34VEURPuFB3DUuejMjFeJXj8Dc5if025AepI6HQxmWycQ0vWYkoOm56LyxGoYbqNHuiw1pmG7AmuZAr8a7ZbnN7nvB0nV6kEsEoYtDtiOabFEvt5zgmqC8mTVLkk-0T09qqbrCX4vw9HobM1wxrrUvuIh8YE7NXRg0Vp80WOsJW0FFuSeNNrOaO68Et7jxeixN07YlLQm0BCrtmjZz8GQUgvM98CXfbNs2AC_vRQEdesdIgJU9lRUbaLVDWVsDEEFQBcl9npLcWvmR8AD_2Mw59DV-JMyd3j29dItcN7Y5IJhy5nrQbnlzuLeGr_gSrqXSuB2vLpUQV_wgirJN6s_gK6P3bE3DGmebgqgfy3AEgQmKuVAjErBejTVEts9qV9qoC8E29OwwjQMmNrUf4fWt-rEXrDjEphBHLqPZbTfNDUTgMPKlIKUC-sm5MS3uz9aa8-ddSnN5peVUkjztoHRHaBp6Gn6zPSFKa4WJnBXUWS4wEo7MJuaDTLfEJ5SVHPVSNSdqJ_jtLkUSrAnd2Y_e9AObKFWrPR9l8V0k5HGL5MaSvFqamksyt6GPqtjf6CZeX8tkJv81le56WosCoHnldcqYL61VZNhkF0sd7HcJ2AZaTmYcwVSNBlHP_569jljVhDaw7aNMma6ZIyOv6HDvxmvwwfn8KWP9IauB2OgJ6TTwoJsuHuBUxnZt407q8D9ow98V50Ruf4bF8wbt4bx7sfp_wu0ruOx9jun1CbstS-O02qVNYYBdh2",
                "id": "rs_0838ec7fe108ae9501690933c74d2c819594c3850d1bd23288",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762210758,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 384,
        "prompt_tokens": 128,
        "total_tokens": 512,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 320,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.0008,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 3.2e-05,
          "upstream_inference_completions_cost": 0.000768
        }
      },
      "provider": "OpenAI"
    }
  }
]